Equillium, Inc. filings document a clinical-stage biotechnology issuer focused on therapies for severe autoimmune and inflammatory disorders. The company’s disclosures cover EQ504, an investigational AhR modulator, along with operating results, financial condition, research and development priorities, and capital resources tied to biotechnology development.
Regulatory filings include 8-K material-event reports, proxy materials, and registration-related disclosures. These records address annual-meeting matters, board and compensation governance, equity awards, auditor changes, common-stock offering documents, material agreements, shareholder voting matters, and capital-structure information for EQ common stock listed on the Nasdaq Capital Market.
Equillium, Inc. director Mark Pruzanski received a grant of stock options covering 70,000 shares of common stock. The options have an exercise price of $2.8400 per share and bring his directly held option position reported in this filing to 70,000 derivative securities.
According to the terms, the option vests in twelve equal monthly installments starting on the grant date of May 28, 2026, and will in any case be fully vested on the date of Equillium's annual meeting of stockholders following that grant date. The option expires on May 27, 2036.
Equillium, Inc. disclosed that chairman and director Daniel Bradbury received a grant of stock options covering 70,000 shares of common stock. The options have an exercise price of $2.84 per share and expire on May 27, 2036.
The award vests in twelve equal monthly installments beginning on May 28, 2026, and will in any case be fully vested on the date of Equillium’s next annual meeting of stockholders following the grant date. This is a compensation-related equity grant, not an open-market share purchase or sale.
Equillium, Inc. senior vice president and COO Christine Zedelmayer reported a set of option exercises paired with open-market sales of common stock. She exercised employee stock options to acquire 95,833 shares at strike prices between $0.73 and $0.785 per share, then sold 95,833 shares at market prices around the high $2 range. After these transactions, she directly holds 62,586 shares of Equillium common stock. A footnote states that at least part of the sales were made under a pre-arranged Rule 10b5-1 trading plan, indicating they were scheduled in advance.
Equillium, Inc. director Charles Douglas McDermott received a grant of stock options covering 70,000 shares of common stock. The options have an exercise price of $2.84 per share and expire on May 27, 2036.
The award vests in twelve equal monthly installments starting on May 28, 2026, and will in any case be fully vested on the date of Equillium's next annual meeting of stockholders following the grant date. Following this grant, McDermott holds 70,000 derivative securities directly.
Equillium, Inc. director Barbara Troupin received a grant of options to purchase 70,000 shares of common stock at an exercise price of $2.84 per share. These director stock options vest in twelve equal monthly installments starting on May 28, 2026 and will be fully vested no later than the issuer's next annual stockholder meeting following the grant date. After this grant, Troupin holds 70,000 derivative securities directly.
Equillium, Inc. reported results of its 2026 Annual Meeting of Stockholders. Shareholders holding 54,287,329 shares, or 85.86% of the 63,226,556 shares outstanding as of April 1, 2026, were present or represented by proxy.
Stockholders elected Charles McDermott and Bruce Steel as Class II directors to serve until the 2029 annual meeting. Former director Peter Colabuono was not renominated, and the board size was reduced from seven to six directors.
Shareholders approved an amendment allowing a potential reverse stock split of the common stock at a ratio between 1-for-2 and 1-for-20, to be implemented at the board’s discretion. They also approved increasing authorized common shares from 200,000,000 to 400,000,000 and ratified Crowe LLP as independent auditor for the year ending December 31, 2026.
EQ filed a Form 144 reporting proposed sales of Common Stock. The filing lists 65,625 shares associated with Maxim Group and a date of 05/27/2026. It also reports securities sold in the past three months on 03/09/2026 totaling 181,219 shares (value shown $357,212.00).
Equillium, Inc. Schedule 13G/A: ADAR1-related entities and Daniel Schneeberger report indirect beneficial ownership of common stock as of March 31, 2026. ADAR1 Capital Management, LLC is shown with 6,603,754 shares (9.9%); ADAR1 Capital Management GP, LLC with 6,306,184 shares (9.5%). The filing cites 63,226,556 shares outstanding as of March 31, 2026 per the issuer's Form 10-Q. The cover disclosures list constituent holdings and 2,877,095 shares underlying prefunded warrants, and note 557,415 prefunded-warrant shares excluded due to a 9.99% beneficial ownership limitation. The filing states these holdings are indirect, reflecting ADAR1’s roles as investment manager, general partner, and Mr. Schneeberger’s manager/control-person status.
Decheng Capital entities and Xiangmin Cui filed an amendment to a Schedule 13G/A reporting beneficial ownership of common stock of EQ. The filing states ownership figures "as of March 31, 2026" and ties the percentage calculations to March 20, 2026 outstanding shares.
The filing says Fund IV directly holds "3,285,710 shares" and warrants exercisable for "985,713 shares," and Healthcare directly holds "1,161,598 shares" and warrants exercisable for "300,000 shares." The cover rows report 5,733,021 shares (8.9%) for Dr. Cui based on "63,226,556 shares outstanding as of March 20, 2026." Signatures show the report was signed on 05/15/2026.
Equillium, Inc. reported a net loss of $5.3M for the quarter ended March 31, 2026, narrowing from $8.7M a year earlier as research and development spending declined after winding down prior clinical programs. Operating expenses fell to $5.6M from $8.9M, driven mainly by lower clinical and headcount-related costs.
Cash and cash equivalents increased to $61.3M at March 31, 2026 from $30.3M at year-end 2025, primarily due to a March 2026 private placement that raised gross proceeds of about $35.0M through common stock and a large pre-funded warrant. Management believes this cash can fund operations into 2029, but the company still has an accumulated deficit of $221.5M and has not generated product revenue.
Equillium’s main focus is advancing EQ504, a novel aryl hydrocarbon receptor modulator, with plans to start a Phase 1 proof-of-mechanism study in mid-2026 and target ulcerative colitis and other gastrointestinal diseases. Additional preclinical work continues on EQ302 and a multi-cytokine platform, while significant potential future dilution exists from pre-funded warrants, stock options and an unused at-the-market equity program.